1.P190Chronic Myeloid Leukemia Following a Course of S-1 Plus Oxaliplatin Therapy For Advanced Gastric Adenocarcinoma.
Hua WANG ; Zhi-Yong WANG ; Chun-Hong XIN ; Ying-Hui SHANG ; Rui JING ; Fa-Hong YAN ; Si-Zhou FENG
Chinese Medical Journal 2017;130(4):495-496
Adenocarcinoma
;
complications
;
drug therapy
;
metabolism
;
Aged
;
Antineoplastic Agents
;
therapeutic use
;
Fusion Proteins, bcr-abl
;
metabolism
;
Humans
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
;
diagnosis
;
etiology
;
metabolism
;
Male
;
Organoplatinum Compounds
;
therapeutic use
;
Stomach Neoplasms
;
drug therapy
;
metabolism
2.The prognostic value of early BCR-ABL transcripts level in 251 patients with chronic myeloid leukemia after treatment with imatinib.
Xiebing BAO ; Huiying QIU ; Suning CHEN ; Xiao MA ; Xiaowen TANG ; Chengcheng FU ; Aining SUN ; Depei WU
Chinese Journal of Hematology 2015;36(7):553-558
OBJECTIVETo understand the prognostic value of early monitoring BCR-ABL transcripts in patients with chronic myeloid leukemia (CML) after treatment with imatinib, and to provide the information for early assessment of prognosis and treatment options.
METHODSThe clinical data of 251 patients with CML in chronic phase (CML-CP) who received imatinib as first-line therapy were retrospectively analyzed, the progression-free survival (PFS)and overall survival (OS) between different BCR-ABL transcriptional level at 3 and 6 month after imatinib treatment were compared. Meanwhile, Chi-square test and logistic regression were used to analyze the risk factors for disease progression.
RESULTSAt 3 months after imatinib treatment BCR-ABL transcriptional levels>10%, >1%-≤ 10% and ≤ 1% were found in 92, 94 and 64 patients, their PFS were 53.3%, 71.3% and 86.2%, respectively. The results showed that the PFS of patients with low BCR-ABL transcriptional levels was significantly superior to that with high BCR-ABL transcriptional levels for CML at 3 months treatment (P<0.05). The OS of three group did not reach statistical significance (92.4% vs 96.8% vs 93.8%, P> 0.05). When 182 patients received imatinib treatment at 6 months, 22 patients with BCR-ABL transcriptional levels>10%, 50>1% -≤ 10% and 110 ≤ 1%, their PFS were 27.3% vs 66.0% vs 82.7% (P<0.05), the OS of three groups were 86.4% vs 94.0% vs 100%. There were significant differences among the three groups (P<0.05). Logistic regression confirmed that the level of BCR-ABL transcriptional level at 3 and 6 months after imatinib treatment was independent factor to influence the progress of disease.
CONCLUSIONIt is important for the prognosis evaluation of CML patients to monitor BCR-ABL transcriptional level at 3 and 6 months after imatinib treatment.
Antineoplastic Agents ; therapeutic use ; Disease-Free Survival ; Fusion Proteins, bcr-abl ; metabolism ; Humans ; Imatinib Mesylate ; therapeutic use ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; diagnosis ; drug therapy ; Prognosis ; Retrospective Studies ; Risk Factors
3.A Rare Case of Chronic Myelogenous Leukemia and Plasma Cell Myeloma in the Same Patient.
Sunhyun AHN ; Joon Seong PARK ; Jae Ho HAN ; Sung Ran CHO
Annals of Laboratory Medicine 2015;35(3):370-372
No abstract available.
Aged
;
Antineoplastic Agents/therapeutic use
;
Bone Marrow/pathology
;
Fusion Proteins, bcr-abl/genetics/metabolism
;
Humans
;
Imatinib Mesylate/therapeutic use
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/complications/*diagnosis/drug therapy
;
Leukocyte Count
;
Male
;
Multiple Myeloma/complications/*diagnosis/drug therapy
;
Platelet Count
;
Polymerase Chain Reaction
;
Thrombocytosis/etiology
4.A Case with Coexistence of Major and Minor BCR/ABL Fusion Transcript at Lymphoblastic Crisis of Chronic Myelogenous Leukemia in Patients with Major BCR/ABL Positivity during Chronic Phase.
Sang Hyuk PARK ; Hyun Sook CHI ; Young Uk CHO ; Seongsoo JANG ; Chan Jeoung PARK ; Ho Joon IM
Annals of Laboratory Medicine 2013;33(1):80-83
No abstract available.
Adolescent
;
Antineoplastic Agents/therapeutic use
;
Benzamides/therapeutic use
;
Chromosome Deletion
;
Chromosomes, Human, Pair 7
;
Drug Resistance, Neoplasm
;
Fusion Proteins, bcr-abl/genetics/*metabolism
;
Humans
;
Immunophenotyping
;
Karyotyping
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*diagnosis/drug therapy/metabolism
;
Male
;
Piperazines/therapeutic use
;
Pyrimidines/therapeutic use
;
Real-Time Polymerase Chain Reaction
5.Persistent suboptimal molecular response in a patient with chronic myelogenous leukemia and Klinefelter syndrome.
Rajshekhar CHAKRABORTY ; Shiva Kumar Reddy MUKKAMALLA ; Kranthi SINGAM ; Natalia CALDERON
The Korean Journal of Internal Medicine 2014;29(6):827-829
No abstract available.
Adult
;
Antineoplastic Agents/therapeutic use
;
*Chromosome Deletion
;
*Chromosomes, Human, Pair 9
;
Cytogenetic Analysis
;
DNA Mutational Analysis
;
Fusion Proteins, bcr-abl/*antagonists & inhibitors/genetics/metabolism
;
Gene Expression Regulation
;
Humans
;
Incidental Findings
;
Klinefelter Syndrome/complications/diagnosis/*genetics
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/complications/diagnosis/*drug therapy/enzymology/genetics
;
Male
;
Molecular Targeted Therapy
;
Protein Kinase Inhibitors/*therapeutic use
;
Remission Induction
;
Time Factors
;
Treatment Outcome
6.A Case of Isolated Lymphoblastic Relapse of the Central Nervous System in a Patient with Chronic Myelogenous Leukemia Treated with Imatinib.
Mi Jung PARK ; Pil Whan PARK ; Yiel Hea SEO ; Kyung Hee KIM ; Ja Young SEO ; Ji Hun JEONG ; Moon Jin KIM ; Jin Woo JEONG ; Jeong Yeal AHN ; Jinny PARK
Annals of Laboratory Medicine 2014;34(3):247-251
No abstract available.
Antineoplastic Agents/*therapeutic use
;
Benzamides/*therapeutic use
;
Central Nervous System Neoplasms/*diagnosis
;
Fusion Proteins, bcr-abl/genetics
;
Humans
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy
;
Leukocytes/metabolism/pathology
;
Male
;
Middle Aged
;
Neoplasm Recurrence, Local
;
Piperazines/*therapeutic use
;
Pyrimidines/*therapeutic use
7.The predictive value of early molecular response in chronic myeloid leukaemia patients treated with imatinib in a single real-world medical centre in a developing country.
Ping Chong BEE ; Veera SEKARAN ; Richard Rui Jie NG ; Ting Yi KWEH ; Gin Gin GAN
Singapore medical journal 2017;58(3):150-154
INTRODUCTIONThe prognosis of patients with chronic myeloid leukaemia (CML) has improved since the introduction of imatinib. However, patients who do not achieve complete cytogenetic response (CCyR) and major molecular response (MMR) have poorer prognosis. Recent clinical trials have demonstrated that early and deeper cytogenetic and molecular responses predict a better long-term outcome. This study aimed to analyse the relationship between early molecular response and clinical outcome in a real-life setting.
METHODSThis retrospective study included all patients with CML, in chronic or accelerated phase, who were treated with imatinib at University of Malaya Medical Centre, Malaysia.
RESULTSA total of 70 patients were analysed. The median follow-up duration was 74 months, and the cumulative percentages of patients with CCyR and MMR were 80.0% and 65.7%, respectively. Overall survival (OS) and event-free survival (EFS) at ten years were 94.3% and 92.9%, respectively. Patients who achieved CCyR and MMR had significantly better OS and EFS than those who did not. At six months, patients who had a BCR-ABL level ≤ 10% had significantly better OS and EFS than those who had a BCR-ABL level > 10%. The target milestone of CCyR at 12 months and MMR at 18 months showed no survival advantage in our patients.
CONCLUSIONOur data showed that imatinib is still useful as first-line therapy. However, vigilant monitoring of patients who have a BCR-ABL level > 10% at six months of treatment should be implemented so that prompt action can be taken to provide the best outcome for these patients.
Academic Medical Centers ; Adult ; Antineoplastic Agents ; therapeutic use ; Cytogenetics ; Disease-Free Survival ; Female ; Follow-Up Studies ; Fusion Proteins, bcr-abl ; metabolism ; Humans ; Imatinib Mesylate ; therapeutic use ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; diagnosis ; drug therapy ; genetics ; Malaysia ; Male ; Middle Aged ; Predictive Value of Tests ; Prognosis ; Retrospective Studies ; Treatment Outcome ; Universities